Amcor to report Half Year 2022 results
ZURICH, Jan. 19, 2022 /PRNewswire/ -- Amcor plc (NYSE: AMCR; ASX: AMC) will announce its Half Year 2022 results for the six months ended 31 December 2021 after the US market closes on Tuesday 1 February 2022. A conference call and webcast to discuss the results will be held at 5.30pm US Eastern Standard Time on Tuesday 1 February 2022 /...
Malaysian-Made ProDetect(R) Rapid Test-Kit Scores 100% Accuracy in International Assessment
GEORGE TOWN, Malaysia, March 2, 2022 /PRNewswire/ -- As the Omicron variant takes hold in Malaysia, the availability of high accuracy Antigen Test Kits is increasingly vital in the drive to identify infection early on and prevent further spread in the community. The ProDetect® COVID-19 Antigen Rapid Test, manufactured in Malaysia by Medical Innovation Ventures Sdn Bhd (Mediven®), recently...
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
First of its kind initiative in India bringing wearable technology for post-surgery care. NEW DELHI and LONDON and SINGAPORE, March 18, 2022 /PRNewswire/ -- Manipal Hospitals, the second-largest healthcare services provider in India, today announced a strategic partnership with ConnectedLife built with Google Cloud to use Fitbit's wearable technology with ConnectedLife's virtual platform to...
China International Medical Equipment Fair 2023 Held in Shanghai in May, Showcasing Cutting-Edge Healthcare Technologies
SHANGHAI, May 15, 2023 /PRNewswire/ -- The 87th edition of the China International Medical Equipment Fair (CMEF) has opened its door to the world in Shanghai. Hosted from May 14 – 17th, the show once again brought together the latest and the great solutions created to drive innovations and push the boundaries of the healthcare field to address the...
EW Nutrition launches Ventar D, the next-generation gut health optimizer
VISBEK, Germany, Oct. 18, 2021 /PRNewswire/ -- EW Nutrition announces the launch of a best-in-class next generation gut health modifier. Ventar D is an innovative proprietary blend of phytomolecules with a novel delivery mechanism. Ventar D addresses key requirements of the animal nutrition industry. The product has been formulated to support gut health and improve performance, resulting in an increase...
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer
HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People's Republic of China to initiate a phase II clinical trial for monotherapy or...
Successful 2020 Tang Prize Award Ceremony Highlights Laureates’ Achievements and Influence
TAIPEI, Nov. 20, 2021 /PRNewswire/ -- The 2020 Tang Prize Award Ceremony took place virtually at 2p.m. (GMT+8) on November 20. Eight 2020 recipients of the prize from seven countries, including the U.S., the U.K., Japan, Singapore, Bangladesh, Colombia, and Lebanon, attended this heartwarming event remotely, where they were greeted with congratulations and applause from audiences all over the...
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203) has successfully completed the enrollment of all patients in China, and the interim analysis is expected in the...
Meihua International Medical Technologies Co., Ltd. Announces Pricing of $36,000,000 Initial Public Offering
YANGZHOU, China, Feb. 16, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced the pricing of its initial public offering (the "Offering") of 3,600,000 ordinary shares at a public offering price of...
TransThera Announces that the IND Application of TT-01488, a Non-covalent Reversible BTK Inhibitor, for the Treatment of B-Cell Lymphomas has been Approved by the FDA in the US and...
NANJING, China, Feb. 18, 2022 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. ("TransThera") announced that the U.S. Food and Drug Administration ("FDA") approved the Investigational New Drug ("IND") application of TT-01488, a non-covalent reversible Bruton's Tyrosine Kinase ("BTK") inhibitor, for the treatment of B-cell lymphomas on January 24, 2022, and TransThera will initiate the Phase I clinical trials in the U.S....
